Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Kevin Hrusovsky, Nicolas Barthelemy

Premium

Quanterix has named Kevin Hrusovsky executive chairman of its board of directors.
Hrusovsky will replace Martin Madaus, who gave up his chairman seat to be chairman and CEO of Ortho-Clinical Diagnostics but who will remain on the Quanterix board.

Hrusovsky formerly was president of PerkinElmer Life Sciences & Technology. He was CEO of Caliper Life Sciences and joined PerkinElmer after that firm acquired Caliper in 2011 for $600 million. Hrusovsky also previously served as CEO of Zymark, and he was president of FMC Corporation's Pharmaceuticals and International Agricultural Products.


Repligen has appointed Nicolas Barthelemy to its board of directors. He spent the last nine years at Life Technologies, until Thermo Fisher Scientific acquired it, most recently serving as Life Tech's president of global commercial operations. Prior to joining Life Tech, he was vice president of manufacturing at Biogen and also the general manager for the company's manufacturing organization.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.